Raquel Grau
Publications by Year
Research Areas
Systemic Lupus Erythematosus Research, Inflammatory mediators and NSAID effects, Monoclonal and Polyclonal Antibodies Research, Peroxisome Proliferator-Activated Receptors, Cancer, Lipids, and Metabolism
Most-Cited Works
- → Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a(2001)435 cited
- → Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1(2006)83 cited
- → Inhibition of Activator Protein 1 Activation, Vascular Endothelial Growth Factor, and Cyclooxygenase-2 Expression by 15-Deoxy-Δ12,14-Prostaglandin J2 in Colon Carcinoma Cells: Evidence for a Redox-Sensitive Peroxisome Proliferator-Activated Receptor-γ-Independent Mechanism(2004)53 cited
- → Systemic lupus erythematosus: clinical expression and anti-Ro/SS—A response in patients with and without lesions of subacute cutaneous lupus erythematosus(1997)28 cited
- → Autoimmune phenomena in children with Human Immunodeficiency Virus infection and Acquired Immunodeficiency Syndrome(1994)16 cited
- → Role of Peroxisome Proliferator‐Activated Receptor Alpha in the Control of Cyclooxygenase 2 and Vascular Endothelial Growth Factor: Involvement in Tumor Growth(2008)15 cited
- Anti-Sa sera from patients with rheumatoid arthritis contain at least 2 different subpopulations of anti-Sa antibodies.(2002)
- Anti-BB'-Sm antibodies, anticardiolipin antibodies, and thrombosis in systemic lupus erythematosus.(1998)
- Anticuerpos anti-U1-RNP no precipitantes en pacientes con lupus eritematoso sistémico(1999)
- Mucosal adjuvants and strategy for overcome multiples vaccine doses(2016)